SGEN [NASD]
Seagen Inc.
Index- P/E- EPS (ttm)-3.77 Insider Own0.60% Shs Outstand183.65M Perf Week31.00%
Market Cap24.59B Forward P/E- EPS next Y-1.22 Insider Trans-35.69% Shs Float182.57M Perf Month-4.80%
Income-689.50M PEG- EPS next Q-0.86 Inst Own90.60% Short Float1.60% Perf Quarter14.48%
Sales1.67B P/S14.73 EPS this Y-210.10% Inst Trans-1.76% Short Ratio2.75 Perf Half Y-20.37%
Book/sh16.33 P/B8.73 EPS next Y75.60% ROA-18.10% Target Price159.88 Perf Year-3.68%
Cash/sh11.31 P/C12.60 EPS next 5Y39.20% ROE-21.90% 52W Range105.43 - 192.79 Perf YTD-7.80%
Dividend- P/FCF- EPS past 5Y-30.10% ROI-22.20% 52W High-26.06% Beta0.84
Dividend %- Quick Ratio4.70 Sales past 5Y30.40% Gross Margin79.90% 52W Low35.20% ATR7.74
Employees2675 Current Ratio5.20 Sales Q/Q28.50% Oper. Margin-41.50% RSI (14)57.99 Volatility7.45% 5.17%
OptionableYes Debt/Eq0.00 EPS Q/Q-10.90% Profit Margin-41.30% Rel Volume1.91 Prev Close135.63
ShortableYes LT Debt/Eq0.00 EarningsApr 28 AMC Payout- Avg Volume1.06M Price142.54
Recom2.10 SMA208.31% SMA502.97% SMA200-5.76% Volume2,010,624 Change5.09%
Feb-10-22Reiterated Wolfe Research Peer Perform $195 → $146
Feb-10-22Reiterated SVB Leerink Outperform $179 → $155
Feb-10-22Reiterated RBC Capital Mkts Sector Perform $154 → $132
Feb-10-22Reiterated Piper Sandler Neutral $165 → $150
Feb-10-22Reiterated Needham Buy $200 → $180
Feb-10-22Reiterated Morgan Stanley Overweight $175 → $170
Feb-10-22Reiterated H.C. Wainwright Buy $200 → $170
Feb-10-22Reiterated BofA Securities Buy $210 → $170
Jan-31-22Upgrade Morgan Stanley Equal-Weight → Overweight $178 → $175
Nov-09-21Initiated Wolfe Research Peer Perform $195
Oct-15-21Resumed BTIG Research Neutral
May-17-21Initiated Evercore ISI In-line
Mar-31-21Initiated Credit Suisse Neutral $145
Feb-01-21Downgrade RBC Capital Mkts Outperform → Sector Perform $188 → $186
Jan-15-21Upgrade BofA Securities Neutral → Buy $215
Sep-22-20Reiterated Stifel Hold $145 → $165
Aug-24-20Resumed Berenberg Buy $187
Jul-31-20Reiterated H.C. Wainwright Buy $175 → $200
Jul-24-20Downgrade Piper Sandler Overweight → Neutral
May-26-20Initiated JMP Securities Mkt Outperform $185
May-16-22 02:02PM  
06:00AM  
May-12-22 10:57AM  
May-09-22 04:33PM  
04:08PM  
06:00AM  
Apr-28-22 05:45PM  
04:02PM  
08:00AM  
Apr-22-22 12:14AM  
Apr-21-22 03:01PM  
Apr-20-22 09:00AM  
Apr-13-22 11:45AM  
11:45AM  
Apr-08-22 03:23PM  
01:19PM  
Apr-07-22 08:00AM  
Mar-16-22 06:30AM  
Mar-11-22 11:30AM  
Mar-01-22 08:00AM  
Feb-28-22 08:00AM  
08:00AM  
Feb-24-22 10:00AM  
10:00AM  
Feb-16-22 05:20AM  
Feb-14-22 05:00PM  
05:00PM  
Feb-09-22 05:15PM  
04:02PM  
Feb-08-22 09:38AM  
08:00AM  
Feb-07-22 09:38PM  
Feb-04-22 03:59PM  
Feb-03-22 08:00AM  
Feb-02-22 03:01PM  
01:38PM  
Feb-01-22 08:00AM  
Jan-24-22 01:38PM  
Jan-18-22 05:00PM  
08:00AM  
Jan-17-22 10:53AM  
Dec-24-21 12:38AM  
Dec-23-21 08:38AM  
Dec-21-21 06:38PM  
Dec-20-21 08:00AM  
Dec-19-21 06:38AM  
Dec-18-21 12:38AM  
Dec-17-21 06:40AM  
Dec-15-21 12:38AM  
Dec-13-21 04:38PM  
Dec-12-21 06:00PM  
Dec-09-21 10:15PM  
05:38PM  
06:38AM  
Dec-08-21 10:05PM  
06:00PM  
Nov-19-21 09:33AM  
Nov-15-21 10:44AM  
Nov-09-21 08:54AM  
Nov-04-21 09:31AM  
Oct-29-21 07:01AM  
Oct-28-21 05:45PM  
04:02PM  
Oct-21-21 03:03PM  
Oct-19-21 01:09PM  
Oct-12-21 09:35AM  
08:00AM  
08:00AM  
Oct-07-21 08:00AM  
Sep-28-21 08:00AM  
Sep-27-21 03:00AM  
03:00AM  
Sep-20-21 05:05PM  
05:03PM  
05:00PM  
Sep-19-21 11:30AM  
Sep-13-21 11:18AM  
Sep-09-21 08:00AM  
Sep-08-21 08:00AM  
Aug-17-21 01:15PM  
Aug-09-21 06:00AM  
Jul-30-21 10:03AM  
Jul-29-21 05:25PM  
04:02PM  
Jul-22-21 03:03PM  
Jul-09-21 02:10PM  
02:10PM  
Jul-08-21 08:00AM  
Jun-28-21 09:43AM  
Jun-16-21 06:38AM  
Jun-03-21 06:00AM  
Jun-02-21 08:00AM  
May-25-21 01:12PM  
May-19-21 05:00PM  
05:00PM  
Apr-30-21 03:01AM  
Apr-29-21 05:25PM  
04:02PM  
02:30PM  
08:00AM  
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SIEGALL CLAY BPresident & CEOMay 12Option Exercise26.1017,043444,822676,653May 13 07:13 PM
SIEGALL CLAY BPresident & CEOMay 12Sale125.6917,0432,142,117666,060May 13 07:13 PM
DANSEY ROGER DChief Medical OfficerApr 21Sale144.1565293,98676,975Apr 22 08:27 PM
SIEGALL CLAY BPresident & CEOApr 20Sale144.321,885272,041666,060Apr 22 08:34 PM
SIMPSON TODD EChief Financial OfficerApr 20Sale144.3256781,829127,891Apr 22 08:32 PM
LIU JEAN IChief Legal OfficerApr 20Sale144.3240157,87275,946Apr 22 08:31 PM
ROMP CHARLES REVP, CommercialApr 20Sale144.3231946,03849,816Apr 22 08:30 PM
HIMES VAUGHN BChief Technical OfficerApr 20Sale144.3257482,83959,064Apr 22 08:29 PM
DANSEY ROGER DChief Medical OfficerApr 20Sale144.32787113,57977,627Apr 22 08:27 PM
GRYSKA DAVID WDirectorApr 19Option Exercise20.064,00080,24048,044Apr 21 06:37 PM
GRYSKA DAVID WDirectorApr 19Sale143.954,000575,78346,250Apr 21 06:37 PM
SIEGALL CLAY BPresident and CEOApr 07Option Exercise26.1017,043444,822672,637Apr 08 09:41 PM
SIEGALL CLAY BPresident and CEOApr 07Sale154.2317,0432,628,610667,945Apr 08 09:41 PM
BAKER BROS. ADVISORS LPDirectorMar 08Option Exercise20.0635,000702,10042,965,004Mar 10 04:39 PM
SIEGALL CLAY BPresident & CEOMar 07Option Exercise26.1017,043444,822674,588Mar 09 07:42 PM
SIEGALL CLAY BPresident & CEOMar 07Sale134.3517,0432,289,655667,945Mar 09 07:42 PM
HIMES VAUGHN BChief Technical OfficerMar 03Option Exercise26.1012,000313,20070,343Mar 04 07:24 PM
HIMES VAUGHN BChief Technical OfficerMar 03Sale127.0512,0001,524,55859,500Mar 04 07:24 PM
Simonian Nancy ADirectorMar 02Option Exercise20.0425,000501,00052,500Mar 04 05:09 PM
GRYSKA DAVID WDirectorFeb 07Option Exercise20.064,50090,27048,621Feb 09 06:58 PM
SIEGALL CLAY BPresident & CEOFeb 07Option Exercise26.1017,043444,822676,930Feb 09 07:02 PM
GRYSKA DAVID WDirectorFeb 07Sale138.764,500624,44146,250Feb 09 06:58 PM
SIEGALL CLAY BPresident & CEOFeb 07Sale139.9717,0432,385,566667,945Feb 09 07:02 PM
DANSEY ROGER DChief Medical OfficerFeb 03Sale136.1470395,70678,244Feb 04 05:54 PM
DANSEY ROGER DChief Medical OfficerFeb 02Sale137.58739101,67278,947Feb 04 05:54 PM
GRYSKA DAVID WDirectorJan 28Option Exercise20.064,50090,27048,803Feb 01 06:42 PM
GRYSKA DAVID WDirectorJan 28Sale122.564,500551,53946,250Feb 01 06:42 PM
GRYSKA DAVID WDirectorJan 14Option Exercise20.064,50090,27050,750Jan 19 06:26 PM
GRYSKA DAVID WDirectorJan 14Sale135.244,500608,58146,250Jan 19 06:26 PM
SIEGALL CLAY BPresident & CEOJan 07Option Exercise26.1017,044444,848676,108Jan 11 07:14 PM
SIEGALL CLAY BPresident & CEOJan 07Sale144.7317,0442,466,743667,945Jan 11 07:14 PM
DANSEY ROGER DChief Medical OfficerJan 03Sale152.588,6751,323,64879,686Jan 05 05:32 PM
DANSEY ROGER DChief Medical OfficerDec 21Sale155.5828043,56288,361Dec 22 05:33 PM
ROMP CHARLES REVP, CommercialDec 20Sale149.851,323198,25249,973Dec 22 05:34 PM
HIMES VAUGHN BChief Technical OfficerDec 20Sale149.8534551,69859,500Dec 22 05:33 PM
SIEGALL CLAY BPresident & CEODec 20Sale149.851,227183,866667,945Dec 22 05:32 PM
DANSEY ROGER DChief Medical OfficerDec 20Sale149.8528041,95888,641Dec 22 05:33 PM
LIU JEAN IChief Legal OfficerDec 20Sale149.8527641,35970,432Dec 22 05:31 PM
SIMPSON TODD EChief Financial OfficerDec 20Sale149.8534551,698128,458Dec 22 05:31 PM
SIEGALL CLAY BPresident & CEODec 07Option Exercise26.1045,4491,186,219683,863Dec 09 06:49 PM
SIEGALL CLAY BPresident & CEODec 07Sale148.6645,4496,756,632669,172Dec 09 06:49 PM
BAKER BROS. ADVISORS LPDirectorDec 01Sale161.2193,45115,064,9404,069,762Dec 02 06:51 PM
BAKER BROS. ADVISORS LPDirectorNov 30Sale160.33301,44448,331,4514,077,649Dec 02 06:51 PM
HIMES VAUGHN BChief Technical OfficerNov 11Option Exercise26.106,000156,60065,845Nov 12 06:51 PM
HIMES VAUGHN BChief Technical OfficerNov 11Sale178.636,0001,071,77459,845Nov 12 06:51 PM
SIMPSON TODD EChief Financial OfficerNov 04Option Exercise46.372,15699,974128,803Nov 05 05:21 PM
LIU JEAN IGC/EVP, Leg AffairsNov 04Option Exercise46.371,61774,98070,708Nov 05 05:21 PM
SIMPSON TODD EChief Financial OfficerNov 03Option Exercise44.0940,2321,773,829166,879Nov 05 05:21 PM
SIMPSON TODD EChief Financial OfficerNov 03Sale185.0040,2327,442,920126,647Nov 05 05:21 PM
LIU JEAN IGC/EVP, Leg AfairsNov 01Option Exercise35.9534,8761,253,792103,967Nov 03 09:18 PM
HIMES VAUGHN BChief Technical OfficerNov 01Option Exercise46.372,15699,97459,845Nov 03 07:20 PM
LIU JEAN IGC/EVP, Leg AfairsNov 01Sale177.4134,8766,187,36969,091Nov 03 09:18 PM
SIMPSON TODD EChief Financial OfficerOct 29Option Exercise41.0433,5641,377,467160,211Nov 02 06:46 PM
SIMPSON TODD EChief Financial OfficerOct 29Sale180.0033,5646,041,523126,647Nov 02 06:46 PM
HIMES VAUGHN BChief Technical OfficerSep 08Option Exercise26.106,000156,60063,488Sep 10 07:22 PM
HIMES VAUGHN BChief Technical OfficerSep 08Sale150.006,000900,00057,488Sep 10 07:22 PM
DANSEY ROGER DChief Medical OfficerAug 31Sale167.524,611772,41485,339Sep 02 08:07 PM
SIEGALL CLAY BPresident & CEOAug 31Sale167.5214,3512,404,015668,458Sep 02 07:59 PM
LIU JEAN IGC/EVP, Legal AffairsAug 31Sale167.523,648611,09768,931Sep 02 07:58 PM
SIMPSON TODD EChief Financial OfficerAug 31Sale167.523,987667,884126,446Sep 02 07:57 PM
HIMES VAUGHN BChief Technical OfficerAug 31Sale167.523,584600,37657,488Sep 02 07:53 PM
ROMP CHARLES REVP, CommercialAug 31Sale167.521,133189,79551,184Sep 02 07:49 PM
SIEGALL CLAY BPresident and CEOAug 31Sale169.9210,4321,772,575682,809Aug 31 09:28 PM
SIEGALL CLAY BPresident and CEOAug 30Sale166.8635,7065,957,816693,241Aug 31 09:28 PM
SIEGALL CLAY BPresident and CEOAug 27Sale169.0514,2942,416,390728,947Aug 31 09:28 PM
ROMP CHARLES REVP, CommercialAug 16Sale154.55777120,08842,410Aug 18 08:29 PM
HIMES VAUGHN BChief Technical OfficerAug 16Sale154.55658101,69752,354Aug 18 08:29 PM
SIEGALL CLAY BPresident & CEOAug 16Sale154.552,789431,051712,420Aug 18 08:29 PM
SIMPSON TODD EChief Financial OfficerAug 16Sale154.5553382,377119,338Aug 18 08:28 PM
LIU JEAN IGC/EVP, Leg AffairsAug 16Sale154.55718110,97063,333Aug 18 08:28 PM
DANSEY ROGER DChief Medical OfficerAug 16Sale154.551,657256,09672,778Aug 18 08:28 PM
DANSEY ROGER DChief Medical OfficerAug 13Sale156.5910,0001,565,86774,435Aug 13 09:39 PM
SIEGALL CLAY BPresident & CEOAug 06Option Exercise15.465,79389,560718,885Aug 06 08:28 PM
SIEGALL CLAY BPresident & CEOAug 06Sale159.705,793925,134715,209Aug 06 08:28 PM
SIEGALL CLAY BPresident & CEOAug 05Option Exercise15.4623,560364,238724,471Aug 06 08:28 PM
SIEGALL CLAY BPresident & CEOAug 05Sale163.0823,5603,842,086715,209Aug 06 08:28 PM
SIEGALL CLAY BPresident and CEOJul 02Option Exercise15.4615,268236,043722,621Jul 06 09:40 PM
ROMP CHARLES REVP, CommercialJul 02Sale158.41703111,36243,187Jul 06 08:13 PM
SIEGALL CLAY BPresident and CEOJul 02Sale156.3615,2682,387,233715,209Jul 06 09:40 PM
SIEGALL CLAY BPresident and CEOJul 01Option Exercise15.4614,085217,754721,374Jul 06 09:40 PM
SIEGALL CLAY BPresident and CEOJul 01Sale157.7814,0852,222,376715,209Jul 06 09:40 PM
DANSEY ROGER DChief Medical OfficerJun 16Sale152.2225,1093,822,03484,435Jun 21 06:02 PM
HIMES VAUGHN BChief Technical OfficerJun 07Option Exercise26.101,30334,00854,315Jun 08 08:50 PM
HIMES VAUGHN BChief Technical OfficerJun 07Sale150.001,303195,45053,012Jun 08 08:50 PM
HIMES VAUGHN BChief Technical OfficerJun 03Option Exercise15.4610,697165,37663,709Jun 04 08:21 PM
SIEGALL CLAY BPresident and CEOJun 03Option Exercise15.4629,353453,797723,884Jun 04 08:22 PM
SIEGALL CLAY BPresident and CEOJun 03Sale144.5129,3534,241,801715,209Jun 04 08:22 PM
HIMES VAUGHN BChief Technical OfficerJun 03Sale144.9110,6971,550,09053,012Jun 04 08:21 PM